Concerns About Eye Toxicity Could Limit GSK’s Myeloma Drug Potential
US FDA Flags Safety Ahead Of Meeting
Executive Summary
Company told more measures needed to limit damage to patients' eyes caused by antibody drug conjugate.
You may also be interested in...
GSK’s Myeloma Drug Gets AdComm Backing, But Limitations Remain Clear
The antibody-drug conjugate now looks set for US approval, but its limitations leave plenty of scope for CAR-T and bispecific rivals.
ESMO: Novel Checkpoint Inhibitors From Merck And BMS Show Promise
TIGIT is not the only novel IO mechanism showing promise, with market leaders Merck and BMS showcasing data from other early stage combinations with Opdivo and Keytruda, while Servier presented a possible three-way combo.
ESMO: Merck Sees Keytruda-Lenvima Potential In Melanoma, Hard-To-Treat Cancers
Keytruda-Lenvima picked out as pick of combination therapies from the European cancer congress.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports